A glycoengineered yeast-derived HA1-ferritin nanoparticle vaccine confers protective immunity against H7 avian influenza in chickens.
7 affiliations
- 1College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China.
- 2College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China. [email protected].
- 3Zhongkai University of Agricultural and Engineering, Guangzhou, 510550, China. [email protected].
- 4College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China. [email protected].
- 5State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, 510642, China. [email protected].
- 6Key Laboratory of Zoonoses, Ministry of Agriculture and Rural Affairs, Guangzhou, 510642, China. [email protected].
- 7National and Regional Joint Engineering Laboratory for Medicament of Zoonoses Prevention and Control, Guangzhou, 510642, China. [email protected].
Abstract
H7 subtype avian influenza virus is an important zoonotic pathogen threatening the poultry industry and public health. Recombinant subunit vaccines provide a safer alternative to conventional inactivated vaccines, while yeast expression systems offer advantages of low cost, scalability, and engineering flexibility. However, their application in avian influenza vaccine development remains underexplored. In this study, we use the methylotrophic yeast Komagataella phaffii as a low-cost, industrial-scale platform to produce hemagglutinin-1 (HA1) subunits with programmable N-/O-linked glycosylation. The methanol-utilization-slow (MutS) phenotype strain secreted 1.21 g/L HA1, and compared with the standard methanol-utilization-plus (Mut⁺) phenotype strain, the N-linked and O-linked glycans were significantly reduced [liquid chromatography-mass spectrometry (LC-MS)/MS glycopeptide profile]. Despite hypoglycosylation, the antigen retained native conformation, binding H7-specific mAb Q74 with a KD of 1.34 × 10⁻⁷ M. SpyTag/SpyCatcher-directed conjugation to ferritin drove quantitative self-assembly into 30 nm virus-like nanoparticles. Formulated with CpG-ODN 1826, the HA1-MutS-ferritin candidate elicited Hemagglutination inhibition (HI) titers of 6.7 log₂ in specific pathogen-free (SPF) leghorns at 28 days post-immunization (dpi), significantly enhancing HA1-specific IgY responses (p < 0.0001) while sustaining high-level circulating CD4⁺ T cells. At 28 dpi, chickens were challenged with 10⁶ embryo infectious dose (EID)₅₀ of H7N9 avian influenza virus; the formulation conferred 100% clinical protection and accelerated viral clearance, matching the performance of conventional inactivated vaccines. Yeast-based processes significantly reduce downstream purification costs and eliminate reliance on chicken embryos, providing a scalable and biosafe platform for rapid avian influenza control.
Related
- H5 influenza virus mRNA-lipid nanoparticle (LNP) vaccination elicits adaptive immune responses in Holstein calves
- Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025
- Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice
- Protective immunity to clinical malaria is modified by the genetic diversity of
- Epitope-guided optimization improves the protective efficacy of NA-based mRNA vaccines against seasonal influenza A(H3N2) virus.
BibTeX
@article{liu2026glycoengineered,
title = {{A glycoengineered yeast-derived HA1-ferritin nanoparticle vaccine confers protective immunity against H7 avian influenza in chickens.}},
author = {Yutong Liu and Yunlin Shao and Bo Su and Peiqi Liu and Yifeng Huang and Han Zheng and Siqi Xu and Yishan Zhao and Qianyu Li and Ming Liao and Saixiang Feng},
journal = {Veterinary research},
year = {2026},
month = oct,
doi = {10.1186/s13567-026-01867-y},
url = {https://europepmc.org/article/MED/42958438},
note = {CC BY},
}
RIS
TY - JOUR
TI - A glycoengineered yeast-derived HA1-ferritin nanoparticle vaccine confers protective immunity against H7 avian influenza in chickens.
AU - Yutong Liu
AU - Yunlin Shao
AU - Bo Su
AU - Peiqi Liu
AU - Yifeng Huang
AU - Han Zheng
AU - Siqi Xu
AU - Yishan Zhao
AU - Qianyu Li
AU - Ming Liao
AU - Saixiang Feng
PY - 2026
DA - 2026/10/29
JO - Veterinary research
DO - 10.1186/s13567-026-01867-y
UR - https://europepmc.org/article/MED/42958438
AB - H7 subtype avian influenza virus is an important zoonotic pathogen threatening the poultry industry and public health. Recombinant subunit vaccines provide a safer alternative to conventional inactivated vaccines, while yeast expression systems offer advantages of low cost, scalability, and engineering flexibility. However, their application in avian influenza vaccine development remains underexplored. In this study, we use the methylotrophic yeast Komagataella phaffii as a low-cost, industrial-scale platform to produce hemagglutinin-1 (HA1) subunits with programmable N-/O-linked glycosylation. The methanol-utilization-slow (MutS) phenotype strain secreted 1.21 g/L HA1, and compared with the standard methanol-utilization-plus (Mut⁺) phenotype strain, the N-linked and O-linked glycans were significantly reduced [liquid chromatography-mass spectrometry (LC-MS)/MS glycopeptide profile]. Despite hypoglycosylation, the antigen retained native conformation, binding H7-specific mAb Q74 with a KD of 1.34 × 10⁻⁷ M. SpyTag/SpyCatcher-directed conjugation to ferritin drove quantitative self-assembly into 30 nm virus-like nanoparticles. Formulated with CpG-ODN 1826, the HA1-MutS-ferritin candidate elicited Hemagglutination inhibition (HI) titers of 6.7 log₂ in specific pathogen-free (SPF) leghorns at 28 days post-immunization (dpi), significantly enhancing HA1-specific IgY responses (p < 0.0001) while sustaining high-level circulating CD4⁺ T cells. At 28 dpi, chickens were challenged with 10⁶ embryo infectious dose (EID)₅₀ of H7N9 avian influenza virus; the formulation conferred 100% clinical protection and accelerated viral clearance, matching the performance of conventional inactivated vaccines. Yeast-based processes significantly reduce downstream purification costs and eliminate reliance on chicken embryos, providing a scalable and biosafe platform for rapid avian influenza control.
SN - 0928-4249
SN - 1297-9716
ER -